H(2) inhalation therapy in patients with moderate COVID-19 (H(2)COVID): a prospective ascending-dose phase I clinical trial.
- DOI
- 10.1128/aac.00573-24
- Published
- 2024 Aug 7
- Container
- Antimicrobial agents and chemotherapy
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1128/aac.00573-24,
title = {H(2) inhalation therapy in patients with moderate COVID-19 (H(2)COVID): a prospective ascending-dose phase I clinical trial.},
author = {Salomez-Ihl C and Giai J and Barbado M and Paris A and Touati S and Alcaraz JP and Tanguy S and Leroy C and Lehmann A and Degano B and Gavard M and Bedouch P and Pavese P and Moreau-Gaudry A and Roustit M and Boucher F and Cinquin P and Brion JP},
year = {2024},
journal = {Antimicrobial agents and chemotherapy},
doi = {10.1128/aac.00573-24},
url = {https://doi.org/10.1128/aac.00573-24}
}RIS
TY - JOUR TI - H(2) inhalation therapy in patients with moderate COVID-19 (H(2)COVID): a prospective ascending-dose phase I clinical trial. AU - Salomez-Ihl C AU - Giai J AU - Barbado M AU - Paris A AU - Touati S AU - Alcaraz JP AU - Tanguy S AU - Leroy C AU - Lehmann A AU - Degano B AU - Gavard M AU - Bedouch P AU - Pavese P AU - Moreau-Gaudry A AU - Roustit M AU - Boucher F AU - Cinquin P AU - Brion JP PY - 2024 JO - Antimicrobial agents and chemotherapy DO - 10.1128/aac.00573-24 UR - https://doi.org/10.1128/aac.00573-24 ER -
APA
C, S., J, G., M, B., A, P., S, T., JP, A., S, T., C, L., A, L., B, D., M, G., P, B., P, P., A, M., M, R., F, B., P, C., & JP, B. (2024). H(2) inhalation therapy in patients with moderate COVID-19 (H(2)COVID): a prospective ascending-dose phase I clinical trial.. Antimicrobial agents and chemotherapy. https://doi.org/10.1128/aac.00573-24
Source records
- pubmed · retrieved 2026-09-25T11:18:46.318Z